Compare SNN & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNN | PODD |
|---|---|---|
| Founded | 1856 | 2000 |
| Country | United Kingdom | United States |
| Employees | 16988 | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 17.0B |
| IPO Year | N/A | 2007 |
| Metric | SNN | PODD |
|---|---|---|
| Price | $33.95 | $204.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $36.25 | ★ $347.55 |
| AVG Volume (30 Days) | 696.1K | ★ 775.0K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $8.61 | $24.59 |
| Revenue Next Year | $5.60 | $19.18 |
| P/E Ratio | $64.97 | ★ $58.10 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $25.45 | $194.61 |
| 52 Week High | $38.79 | $354.88 |
| Indicator | SNN | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 36.58 |
| Support Level | $32.03 | N/A |
| Resistance Level | $37.23 | $299.75 |
| Average True Range (ATR) | 0.56 | 6.04 |
| MACD | 0.32 | 0.94 |
| Stochastic Oscillator | 78.35 | 42.65 |
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.